title: [Intermittent androgen deprivation (IAD) for advanced prostate cancer. Why not the standard of therapy?].
abstract: OBJECTIVE
  To review the literature and present a contemporary image of androgen deprivation for prostate cancer.
  
  
  METHODS
  We conducted a PubMed search on intermittent androgen deprivation. Articles obtained on intermittent androgen deprivation (IAD) and the experiences at Institut Montsouris were used for the review.
  
  
  RESULTS
  IAD is an approach to hormonal deprivation that holds effective cancer control while preventing the morbidity associated with continuous androgen blockade. IAD nuances have been assessed by urological community teams in order to verify its possible potential benefits. Evidence based approach supports the idea of IAD as a standard of therapy for advanced prostate cancer requiring hormone deprivation. Variation among medical teams' criteria for the treatment and surveillance await standardization.
  
  
  CONCLUSIONS
  Reassessing the gold standard of hormonal blockade in advanced prostate cancer is mandatory.The undeniable evolution of IAD needs to be embraced by the urological community.
authors: Urology Department, Institut Mutualiste Montsouris, Université Paris Descartes, Paris, France. dominique.prapotnich@imm.fr
authors: Dominique
authors: D
authors: Prapotnich
authors: Rafael
authors: R
authors: Sánchez-Salas
authors: Xavier
authors: X
authors: Cathelineau
authors: Oleksandr
authors: O
authors: Stakhovskyi
authors: José E A
authors: JE
authors: Rocha
authors: Guy
authors: G
authors: Vallancien
mesh_terms: D000726:Androgen Antagonists / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D018450:Disease Progression; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal